4 completed, 2 active not recruiting. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 4, Active not recruiting 2 |
Follow Multiple Sclerosis, Primary Progressive: new trials by email Literature Review of Multiple Sclerosis, Primary Progressive trials Research Report on Multiple Sclerosis, Primary Progressive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis Fenebrutinib, Ocrelizumab, Placebo matched to ocrelizumab - Multiple Sclerosis, Primary Progressive | Phase 3 | Active not recruiting | Hoffmann-La Roche | 985 | 2020-10-26 | 2026-09-17 |
| A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis Ocrelizumab, Placebo - Multiple Sclerosis, Primary Progressive | Phase 3 | Active not recruiting | Hoffmann-La Roche | 1013 | 2019-08-12 | 2026-02-23 |
| Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS) Ocrelizumab, Lumbar Puncture, Methyloprednisolone - Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive | Phase 3 | Completed | Genentech, Inc. | 131 | 2016-04-29 | 2024-06-04 |
| A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis Placebo, BIIB041 (fampridine) - Multiple Sclerosis, Remittent Progressive, Multiple Sclerosis, Primary Progressive | Phase 3 | Completed | Biogen | 101 | 2013-08-01 | 2017-03-21 |
| Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis Masitinib, Placebo - Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive | Phase 3 | Completed | AB Science | 656 | 2011-08-01 | 2020-04-08 |
| A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis Ocrelizumab, Placebo - Multiple Sclerosis, Primary Progressive | Phase 3 | Completed | Hoffmann-La Roche | 735 | 2011-03-02 | 2024-01-10 |
Multiple Sclerosis, Chronic Progressive (6) · Multiple Sclerosis (2) · Multiple Sclerosis, Relapsing-Remitting (1)
Autoimmune Diseases (6) · Autoimmune Diseases of the Nervous System (6) · Chronic Disease (6) · Demyelinating Autoimmune Diseases, CNS (6) · Demyelinating Diseases (6) · Disease Attributes (6) · Immune System Diseases (6) · Nervous System Diseases (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Multiple Sclerosis (4)
ocrelizumab (4) · 4-Aminopyridine (1) · Histamine Antagonists (1) · Spinal Puncture (1) · fenebrutinib (1) · masitinib (1)
Hoffmann-La Roche (3) · AB Science (1) · Biogen (1) · Genentech, Inc. (1)
Bulgaria (4) · Canada (4) · France (4) · Germany (4) · Poland (4) · Spain (4) · United States (4) · Australia (3) · Greece (3) · Italy (3) · Mexico (3) · Portugal (3) · Romania (3) · Russia (3) · Ukraine (3)
Patrick Vermersch, MD, PhD (1)
PMID 28002688, PMID 30155979, PMID 30415593, PMID 33129442, PMID 33724638, PMID 35190477, PMID 35672926, PMID 36163349, PMID 36792367, PMID 37652990, PMID 38071574, PMID 40258203, PMID 42208561, PMID 42376811
2015 (1), 2018 (1), 2019 (1), 2023 (1)